As Europe Prepares for Ambitious Revisions to His Regulatory Framework to Support the Green Deal’s Targets, Key Findings From the Largest European Hydrogen Mobility Initiative Highlight the Role Hydrogen Can Play
14.1.2021 13:03:00 EET | Business Wire | Press release
A flagship project for hydrogen mobility involving nearly 50 organisations at the forefront of the sector has today published its final report detailing the key findings and learnings. The findings are released at a crucial time as the European Green Deal seeks a 90% reduction in transport related emissions by 2050.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005025/en/
Hydrogen Mobility Europe (H2ME) has completed its first phase and compiled a rich dataset since initiating in 2016: 630 hydrogen fuel cell electric vehicles have been deployed in 10 countries and 37 new hydrogen refuelling stations installed in 8 countries, achieving 14.5 million km driven and 147 tonnes of hydrogen dispensed across 68,000 refuelling events. It is the largest European deployment for hydrogen mobility to date and demonstrates the commercial potential to rollout fuel cell electric vehicles (FCEVs) and hydrogen refuelling stations (HRS) for large and small fleets.
Following the conclusion of its initial phase, H2ME recommends national and international incentives that ensure the dispensed cost of low carbon hydrogen is competitive for vehicle operators to create a level playing field with other zero emission vehicles. National, regional, and local policies that ensure continued development of the industry are also recommended. The expansion of hydrogen infrastructure as a result of H2ME, co-funded by the FCH-JU, means more FCEVs now have access to refuelling stations however the limited infrastructure prevents full operational advantages of FCEVs being realised.
Incentives such as purchase grants and tax exemptions will unlock demand from vehicle operators and bring market confidence to vehicle suppliers. Similarly, financial support applied per unit (kg) of hydrogen sold, similar to the feed in tariffs which were applied to stimulate early renewable energy uptake, will lower the price of green hydrogen at the pump. This will enable high utilisation of refuelling stations, which strengthens its business case, demonstrated by clusters of captive fleets with high mileage and heavy-duty cycles as they have significantly lower costs per kilogram of hydrogen.
The second phase of deployment will focus on developing state of the art refuelling stations, increased options for producing green hydrogen, and targeting a wider range of vehicles (from light duty to heavy duty vehicles). The lessons from phase one show that future hydrogen mobility strategies should focus more on high mileage and heavy-duty applications to provide the anchor demand for new installations. This will provide a stronger business case to the HRS operators.
Hydrogen could play a key role in enabling high mileage applications can transition to zero emission as these applications have specific operational needs such as long range and short refuelling time, that can be met by FCEVs. The overall cost of operating FCEVs in these fleets is expected to decrease rapidly in the coming years. For example, an analysis from the ZEFER project found that for high mileages applications such as taxis, and with hydrogen at €7,5/kg, FCEVs can reach parity on a total cost of ownership basis with petrol/diesel hybrids in the next 5 years.
In Denmark three Hyundai ix35 FCEVs are used by the Municipality of Copenhagen for a variety of duties as part of H2ME. They average 120 km travelled per day, with recorded distances up to 500 km in a single day, and have access to three refuelling stations within driving range. Well-to-wheel (WTW) emissions from FCEVs in Denmark are calculated at 20 gCO2e/km, compared to 34 gCO2e/km for a battery electric vehicle, 47 gCO2e/km for a battery electric SUV and 217 gCO2e/km for a diesel comparator. The use of 100% green certified electrolytic hydrogen is key to the low emissions, however FCEVs still achieve significantly lower WTW emissions than diesel or gasoline vehicles even if using hydrogen derived from fossil fuels. Similar analysis conducted in Germany and France found that FCEVs achieve significant emission savings compared to diesel or gasoline vehicles, even if using fossil-derived hydrogen, and can be even more significantly when using low carbon or green hydrogen.
The fuel cell electric vehicles deployed have completed up to 600 km of driving range on a single tank, and prove reliable with over 99% availability over their operational usage since 2016. The confirmation of technology readiness, emerging business cases and customer proposition in the project shows a path towards commercialisation.
With increasing needs for zero emissions mobility solutions to achieve environmental targets, and economics expecting to improve rapidly at scale, there is a strong case to support the commercial rollout for hydrogen mobility.
Bart Biebuyck, Executive Director at Fuel Cells and Hydrogen Joint Undertaking (FCH JU), said: “The first phase of H2ME has demonstrated that light duty hydrogen fuel cell vehicles are performant and nearing market competition with other zero emissions vehicles for high mileage applications, like taxi fleets. In addition, our flagship project was successful in supporting the onset of a European H2 infrastructure for road transport. Today, Europe has a card to play: By integrating these learnings into the heavy duty truck sector, it can capitalise on best practices of vehicles fleets and infrastructure management, making an essential contribution to a green post-Covid recovery of our economy”.
Ben Madden, Director at Element Energy, said: “We are pleased to share the results and findings of the H2ME 1 project. This project would not have been possible without the support from the FCH JU and commitment of all partners involved. Grants to support early stage commercial deployments are a critical step in the path towards commercialisation and will remain one of the key financial tools at the European level in the coming year to develop solutions for zero-emission mobility. Element Energy is very proud to have coordinated this project and to continue supporting the largest hydrogen mobility initiative in Europe.”
Dr Duncan Yellen, Managing Director at ITM Motive, said: “Participation in the H2ME project has been invaluable in providing insights into both the engineering and customer requirements for our future build programme. Thanks to the learning provided here and through other funded projects we are confident in our ability to provide the best possible designs for building the next generation of Hydrogen Refuelling Stations across the UK to match the needs of heavy duty vehicles, high use car fleets and rail.”
Nikolas Iwan, CEO of H2 Mobility, said: “20 of the more than 90 stations in Germany have been built in the H2ME project. We are proud to be partner in the largest European hydrogen mobility initiative. Collaboration is the key to a successful mobility transition, especially in the next phase were rules and regulations have to be set for the light and heavy duty transport sector.”
Anna Margrét Kornelíusdóttir, Project Manager at Icelandic New Energy Ltd, said: "The Nordic countries have long had a faith in clean hydrogen produced from their abundant renewable energy resources. Our governments have made this clear by implementing generous economic incentives and ambitious strategies.
“H2ME has demonstrated the use and reliability of hydrogen and fuel cell technology for passenger vehicles across Europe and proven the feasibility of hydrogen as a transport fuel.
“Amid rising pressure to reach decarbonisation goals, hydrogen technology represents a low carbon and low emission energy solution that can play a vital role in the next steps addressing a transition to clean energy, not only for passenger vehicles, but also heavy-duty trucks, marine vessels and even aviation”.
- Ends -
Notes to Editor
Download the full report here: https://h2me.eu/wp-content/uploads/2021/01/H2ME_Emerging-Conclusions2020.pdf
Image: https://we.tl/t-rvTibkH4Bz
Caption: 37 new hydrogen refuelling stations have been installed in 8 countries as part of the H2ME project
About H2ME
This €170 million demonstration project is co-funded with €67 million from the Fuel Cells and Hydrogen Joint Undertaking (FCH JU), a public-private partnership supporting fuel cell and hydrogen energy technologies in Europe.
Partners include project lead Element Energy, alongside AGA, Air Liquide, AREVA H2GEN, Audi, BOC, BMW, Cenex, City of Copenhagen (Kobenhavns Kommune), Communauté d’Agglomération Sarreguemines Confluence, CNR, Daimler AG, Danish Hydrogen Fuel, EIFER, GNVERT, H2 Mobility Deutschland, Honda, Hydrogen Denmark (Brintbranchen), Hydrogene de France, hySOLUTIONS, Hyundai, Icelandic New Energy Ltd, Intelligent Energy, Islenska Vetnisfelagid (H2 Iceland), Kerkhof, ITM Power, Linde AG, McPhy Energy, Michelin, Nel Hydrogen, Netherlands Ministry of Infrastructure and Water Management (Ministerie Van Infrastructuur en Waterstaat), Nissan, OMV, OPEN ENERGI, Renault, Renault Trucks, SEMITAN, Stedin, STEP, Symbio, Toyota, The University of Manchester, WaterstofNet.
This project has received funding from the Fuel Cells and Hydrogen 2 Joint Undertaking under grant agreement No 671438 & No 700350. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, Hydrogen Europe and Hydrogen Europe research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005025/en/
Contact information
Declan Shepherd | PR and Social Media Officer at Cenex
Email: Declan.Shepherd@Cenex.co.uk
Website: www.h2me.eu
Twitter: @H2ME_EU
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
